The Experts below are selected from a list of 348 Experts worldwide ranked by ideXlab platform

Hiroshige Mikamo - One of the best experts on this subject based on the ideXlab platform.

  • Antimicrobial efficacies of several antibiotics against Uterine Cervicitis caused by Mycoplasma genitalium
    Journal of Infection and Chemotherapy, 2012
    Co-Authors: Michinori Terada, Koji Izumi, Emiko Ohki, Yuka Yamagishi, Hiroshige Mikamo
    Abstract:

    Mycoplasma genitalium has been shown to be one of the pathogens responsible for Uterine Cervicitis by many studies. However, there are no clinical recommendations for treating M. genitalium -positive Uterine Cervicitis. Our study retrospectively investigated the antimicrobial efficacies of several antibiotics against Uterine Cervicitis caused by M. genitalium . We studied a total of 257 women with M. genitalium -positive Uterine Cervicitis, except for those with chlamydial and gonococcal infections, who were treated with one of the following antibacterial therapies: azithromycin extended release formulation (AZM-SR) 2 g single dose, azithromycin (AZM) 1 g single dose, clarithromycin (CAM) 400 mg/day for 7 days, CAM 400 mg/day for 14 days, moxifloxacin (MFLX) 400 mg/day for 7 days, MFLX 400 mg/day for 14 days, levofloxacin (LVFX) 500 mg/day for 7 days, LVFX 500 mg/day for 14 days, sitafloxacin (STFX) 200 mg/day for 7 days, and STFX 200 mg/day for 14 days. A PCR-based assay was performed to evaluate the microbiological efficacy of eradication in these patients. M. genitalium was eradicated from the Uterine cervix in 19 of the 21 (90.5%) patients treated with AZM-SR 2 g single dose, in 38 of the 42 (90.5%) patients treated with MFLX 400 mg/day for 7 days, in 42 of the 42 (100%) patients treated with MFLX 400 mg/day for 14 days, and in 12 of the 13 (92.3%) patients treated with STFX 200 mg/day for 14 days. In conclusion, AZM-SR 2 g single dose, MFLX 400 mg/day for 14 days, and STFX 200 mg/day for 14 days would each be an effective treatment for M. genitalium infection.

  • Clinical efficacy of clarithromycin against Uterine cervical and pharyngeal Chlamydia trachomatis and the sensitivity of polymerase chain reaction to detect C. trachomatis at various time points after treatment
    Journal of Infection and Chemotherapy, 2003
    Co-Authors: Hiroshige Mikamo, Mochiyoshi Ninomiya, Teruhiko Tamaya
    Abstract:

    The detection and eradication of pharyngeal Chlamydia trachomatis in patients with chlamydial Uterine Cervicitis (commercial sex workers and others) were investigated. Pharyngeal C. trachomatis was detected in 75.0% of the commercial sex workers and in 21.9% of the other subjects. All the pharyngeal C. trachomatis -positive patients had a past history of orogenital contact. Chlamydial infection was treated with clarithromycin for 7 or 14 days. The presence of C. trachomatis was determined by polymerase chain reaction (PCR) on days 8, 15, and 22 after completion of the treatment. In the 7-day treatment group, the eradication rate of pharyngeal C. trachomatis was 53.3%, 56.7%, and 60.0% on days 8, 15, and 22, respectively, after completion of the treatment, while the eradication rate of cervical C. trachomatis was 83.3%, 96.7%, and 100% on days 8, 15, and 22, respectively. The eradication rate of pharyngeal C. trachomatis in the 7-day treatment was significantly lower than that of cervical C. trachomatis , while there was no significant difference in the 14-day treatment. The eradication rate of pharyngeal C. trachomatis in the 14-day treatment was significantly higher than that in the 7-day treatment. Since the DNA of dead organisms may be detected because of high PCR sensitivity, appropriate therapeutic judgment by PCR could be done around day 22 after completion of the treatment.

  • Adequate Levofloxacin Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 2000
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Yin Xiang Hua, Teruhiko Tamaya
    Abstract:

    The in vivo efficacy of levofloxacin (LVFX), one of the most standard new quinolone antimicrobial agents, in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis in women was evaluated. Cervical C. trachomatis was detected by polymerase chain reaction. LVFX at a dosage of 300 mg t.i.d. for 5, 7 and 14 days was orally administered to 18, 33 and 35 Japanese patients, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rate in 5-, 7- or 14-day cases was 44.4, 87.9 or 88.6%, respectively. The recurrence rate of 5-, 7- or 14-day cases was 50.0, 0 or 0%, respectively. Seven-day treatment with LVFX is adequate for and effective in C. trachomatis Uterine Cervicitis.

  • Adequate Macrolide Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya
    Abstract:

    To evaluate in vivo efficacy of macrolides; erythromycin (EM) and clarithromycin (CAM), in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis im women. Cervical C. trachomatis was detected by the polymerase chain reaction. EM was orally administered to 8, 15 and 18 Japanese patients, at a dosage of 600 mg, t.i.d. for 5, 7 and 14 days, respectively. CAM was orally administered to 10, 26 and 19 Japanese patients at a dosage of 400 mg, b.i.d. for 5, 7 and 14 days, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rates after 5, 7 or 14 days of treatment with EM were 1/8, 8/15 or 13/18, respectively. The recurrence rates after 5, 7 or 14 days of treatment with EM were 1/1, 3/8 or 2/13, respectively. On the other hand, the eradication rates after 5, 7 or 14 days of treatment with CAM were 5/10, 26/26 or 19/19, respectively. The recurrence rates after 5, 7 or 14 days of treatment with CAM were 3/5, 0/26 or 0/19, respectively. A 7-day treatment with CAM would be adequate and effective for C. trachomatis Uterine Cervicitis.

  • Effects of levofloxacin once-a-day therapy on Uterine Cervicitis
    The Japanese journal of antibiotics, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya, Yamada Y, Kunihiko Ito, Koji Izumi, Kyoko Kawazoe
    Abstract:

    An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on Uterine Cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days. Of the 102 patients enrolled in the study, 90 were subjected to the analysis. The efficacy rate on Uterine Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 72.0% (36/50) and 82.5% (33/40), respectively. The efficacy rate on Uterine chlamydial Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 88.0% (22/25) and 85.7% (18/21), respectively. Safety was evaluated as "safe" in 88 of the 90 assessable patients (97.8%). Side effects were seen in two cases, which belong to the once-a-day therapy group; mild candidiasis and mild breast distension sense. As the antimicrobial treatment started, the levels of the inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8) in the cervical mucus, decreased. It is suggested that IL-6 and IL-8 can be useful indicators of the antimicrobial treatment in the Uterine Cervicitis. These results suggested that the LVFX once-a-day therapy can be useful on Uterine Cervicitis.

Teruhiko Tamaya - One of the best experts on this subject based on the ideXlab platform.

  • Clinical efficacy of clarithromycin against Uterine cervical and pharyngeal Chlamydia trachomatis and the sensitivity of polymerase chain reaction to detect C. trachomatis at various time points after treatment
    Journal of Infection and Chemotherapy, 2003
    Co-Authors: Hiroshige Mikamo, Mochiyoshi Ninomiya, Teruhiko Tamaya
    Abstract:

    The detection and eradication of pharyngeal Chlamydia trachomatis in patients with chlamydial Uterine Cervicitis (commercial sex workers and others) were investigated. Pharyngeal C. trachomatis was detected in 75.0% of the commercial sex workers and in 21.9% of the other subjects. All the pharyngeal C. trachomatis -positive patients had a past history of orogenital contact. Chlamydial infection was treated with clarithromycin for 7 or 14 days. The presence of C. trachomatis was determined by polymerase chain reaction (PCR) on days 8, 15, and 22 after completion of the treatment. In the 7-day treatment group, the eradication rate of pharyngeal C. trachomatis was 53.3%, 56.7%, and 60.0% on days 8, 15, and 22, respectively, after completion of the treatment, while the eradication rate of cervical C. trachomatis was 83.3%, 96.7%, and 100% on days 8, 15, and 22, respectively. The eradication rate of pharyngeal C. trachomatis in the 7-day treatment was significantly lower than that of cervical C. trachomatis , while there was no significant difference in the 14-day treatment. The eradication rate of pharyngeal C. trachomatis in the 14-day treatment was significantly higher than that in the 7-day treatment. Since the DNA of dead organisms may be detected because of high PCR sensitivity, appropriate therapeutic judgment by PCR could be done around day 22 after completion of the treatment.

  • Adequate Levofloxacin Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 2000
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Yin Xiang Hua, Teruhiko Tamaya
    Abstract:

    The in vivo efficacy of levofloxacin (LVFX), one of the most standard new quinolone antimicrobial agents, in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis in women was evaluated. Cervical C. trachomatis was detected by polymerase chain reaction. LVFX at a dosage of 300 mg t.i.d. for 5, 7 and 14 days was orally administered to 18, 33 and 35 Japanese patients, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rate in 5-, 7- or 14-day cases was 44.4, 87.9 or 88.6%, respectively. The recurrence rate of 5-, 7- or 14-day cases was 50.0, 0 or 0%, respectively. Seven-day treatment with LVFX is adequate for and effective in C. trachomatis Uterine Cervicitis.

  • Adequate Macrolide Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya
    Abstract:

    To evaluate in vivo efficacy of macrolides; erythromycin (EM) and clarithromycin (CAM), in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis im women. Cervical C. trachomatis was detected by the polymerase chain reaction. EM was orally administered to 8, 15 and 18 Japanese patients, at a dosage of 600 mg, t.i.d. for 5, 7 and 14 days, respectively. CAM was orally administered to 10, 26 and 19 Japanese patients at a dosage of 400 mg, b.i.d. for 5, 7 and 14 days, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rates after 5, 7 or 14 days of treatment with EM were 1/8, 8/15 or 13/18, respectively. The recurrence rates after 5, 7 or 14 days of treatment with EM were 1/1, 3/8 or 2/13, respectively. On the other hand, the eradication rates after 5, 7 or 14 days of treatment with CAM were 5/10, 26/26 or 19/19, respectively. The recurrence rates after 5, 7 or 14 days of treatment with CAM were 3/5, 0/26 or 0/19, respectively. A 7-day treatment with CAM would be adequate and effective for C. trachomatis Uterine Cervicitis.

  • Effects of levofloxacin once-a-day therapy on Uterine Cervicitis
    The Japanese journal of antibiotics, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya, Yamada Y, Kunihiko Ito, Koji Izumi, Kyoko Kawazoe
    Abstract:

    An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on Uterine Cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days. Of the 102 patients enrolled in the study, 90 were subjected to the analysis. The efficacy rate on Uterine Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 72.0% (36/50) and 82.5% (33/40), respectively. The efficacy rate on Uterine chlamydial Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 88.0% (22/25) and 85.7% (18/21), respectively. Safety was evaluated as "safe" in 88 of the 90 assessable patients (97.8%). Side effects were seen in two cases, which belong to the once-a-day therapy group; mild candidiasis and mild breast distension sense. As the antimicrobial treatment started, the levels of the inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8) in the cervical mucus, decreased. It is suggested that IL-6 and IL-8 can be useful indicators of the antimicrobial treatment in the Uterine Cervicitis. These results suggested that the LVFX once-a-day therapy can be useful on Uterine Cervicitis.

Jeng-fong Chiou - One of the best experts on this subject based on the ideXlab platform.

  • Elevated lipid peroxidation and disturbed antioxidant enzyme activities in plasma and erythrocytes of patients with Uterine Cervicitis and myoma
    Clinical Biochemistry, 1999
    Co-Authors: Jeng-fong Chiou
    Abstract:

    Objectives: We investigated whether oxidative stress is associated with human Uterine Cervicitis and Uterine myoma. Design and Methods: We measured lipid peroxidation and antioxidant enzymes in plasma and erythrocytes of Cervicitis patients and myoma patients in comparison with matched controls. Thiobarbituric acid-reactive substances (TBARS), a measure of lipid peroxidation, were determined in plasma; glutathione peroxidase (GSHPx) and catalase in erythrocytes; and superoxide dismutase (SOD) in both plasma and erythrocytes. Results: We showed that plasma TBARS were significantly higher (p 0.05) in myoma patients than in controls; catalase activity was 10% higher (p > 0.05) in Cervicitis patients and 13% lower (p > 0.05) in myoma patients than in controls. Neither erythrocyte GSHPx nor catalase activity was significantly correlated with plasma TBARS. Conclusions: The elevated lipid peroxidation and disturbed antioxidant enzyme activities demonstrate the potential of oxidative injury in patients with Uterine Cervicitis and myoma.

Hu M.l. - One of the best experts on this subject based on the ideXlab platform.

  • Elevated lipid peroxidation and disturbed antioxidant enzyme activities in plasma and erythrocytes of patients with Uterine Cervicitis and myoma
    2014
    Co-Authors: Chiou J.f., Hu M.l.
    Abstract:

    Objectives: We investigated whether oxidative stress is associated with human Uterine Cervicitis and Uterine myoma. Design and Methods: We measured lipid peroxidation and antioxidant enzymes in plasma and erythrocytes of Cervicitis patients and myoma patients in comparison with matched controls. Thiobarbituric acid-reactive substances (TBARS), a measure of lipid peroxidation, were determined in plasma; glutathione peroxidase (GSHPx) and catalase in erythrocytes; and superoxide dismutase (SOD) in both plasma and erythrocytes. Results: We showed that plasma TEARS were significantly higher (p < 0.05) in both Cervicitis patients and myoma patients than in controls. Plasma TEARS were significantly (and negatively) correlated with plasma and erythrocyte T-SOD activities in Cervicitis patients only. Plasma T-SOD activity was significantly lower in both groups of patients than in controls whereas erythrocyte T-SOD activity was only significantly lower in myoma patients. The lowered plasma T-SOD activity in the Cervicitis patients was attributed to decreased Mn-SOD activity whereas the lowered plasma T-SOD activity in myoma patients was attributed to decreased activities of both Cu,Zn-SOD and Mn-SOD. Erythrocyte GSHPx activity was 14% higher (p < 0.05) in Cervicitis patients and 11% lower (p > 0.05) in myoma patients than in controls; catalase activity was 10% higher (p > 0.05) in Cervicitis patients and 13% lower (p > 0.05) in myoma patients than in controls. Neither erythrocyte GSHPx nor catalase activity was significantly correlated with plasma TEARS. Conclusions: The elevated lipid peroxidation and disturbed antioxidant enzyme activities demonstrate the potential of oxidative injury in patients with Uterine Cervicitis and myoma. Copyright (C) 1999 The Canadian society of Clinical Chemists

Yasumasa Sato - One of the best experts on this subject based on the ideXlab platform.

  • Adequate Levofloxacin Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 2000
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Yin Xiang Hua, Teruhiko Tamaya
    Abstract:

    The in vivo efficacy of levofloxacin (LVFX), one of the most standard new quinolone antimicrobial agents, in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis in women was evaluated. Cervical C. trachomatis was detected by polymerase chain reaction. LVFX at a dosage of 300 mg t.i.d. for 5, 7 and 14 days was orally administered to 18, 33 and 35 Japanese patients, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rate in 5-, 7- or 14-day cases was 44.4, 87.9 or 88.6%, respectively. The recurrence rate of 5-, 7- or 14-day cases was 50.0, 0 or 0%, respectively. Seven-day treatment with LVFX is adequate for and effective in C. trachomatis Uterine Cervicitis.

  • Adequate Macrolide Treatment Schedules for Uterine Cervicitis Caused by Chlamydia trachomatis
    Chemotherapy, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya
    Abstract:

    To evaluate in vivo efficacy of macrolides; erythromycin (EM) and clarithromycin (CAM), in the different treatment schedules of Chlamydia trachomatis Uterine Cervicitis im women. Cervical C. trachomatis was detected by the polymerase chain reaction. EM was orally administered to 8, 15 and 18 Japanese patients, at a dosage of 600 mg, t.i.d. for 5, 7 and 14 days, respectively. CAM was orally administered to 10, 26 and 19 Japanese patients at a dosage of 400 mg, b.i.d. for 5, 7 and 14 days, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rates after 5, 7 or 14 days of treatment with EM were 1/8, 8/15 or 13/18, respectively. The recurrence rates after 5, 7 or 14 days of treatment with EM were 1/1, 3/8 or 2/13, respectively. On the other hand, the eradication rates after 5, 7 or 14 days of treatment with CAM were 5/10, 26/26 or 19/19, respectively. The recurrence rates after 5, 7 or 14 days of treatment with CAM were 3/5, 0/26 or 0/19, respectively. A 7-day treatment with CAM would be adequate and effective for C. trachomatis Uterine Cervicitis.

  • Effects of levofloxacin once-a-day therapy on Uterine Cervicitis
    The Japanese journal of antibiotics, 1999
    Co-Authors: Hiroshige Mikamo, Yasumasa Sato, Yoh Hayasaki, Teruhiko Tamaya, Yamada Y, Kunihiko Ito, Koji Izumi, Kyoko Kawazoe
    Abstract:

    An investigation was carried out to determine the therapeutic effect of levofloxacin (LVFX) once-a-day oral therapy at the dose of 200 mg/day for 7 days on Uterine Cervicitis, in comparison with LVFX twice-a-day oral therapy at the dose of 200 mg/day for 7 days. Of the 102 patients enrolled in the study, 90 were subjected to the analysis. The efficacy rate on Uterine Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 72.0% (36/50) and 82.5% (33/40), respectively. The efficacy rate on Uterine chlamydial Cervicitis of the once-a-day therapy and twice-a-day therapy groups according to the evaluation of the Drug Efficacy Evaluation Committee were 88.0% (22/25) and 85.7% (18/21), respectively. Safety was evaluated as "safe" in 88 of the 90 assessable patients (97.8%). Side effects were seen in two cases, which belong to the once-a-day therapy group; mild candidiasis and mild breast distension sense. As the antimicrobial treatment started, the levels of the inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8) in the cervical mucus, decreased. It is suggested that IL-6 and IL-8 can be useful indicators of the antimicrobial treatment in the Uterine Cervicitis. These results suggested that the LVFX once-a-day therapy can be useful on Uterine Cervicitis.